KBI Biopharma Inc Sustainability Profile
KBI Biopharma Inc., a leading contract development and manufacturing organisation (CDMO), is headquartered in the United States, with significant operational facilities across Europe and Asia. Founded in 1996, KBI has established itself as a key player in the biopharmaceutical industry, specialising in the development and production of biologics, including monoclonal antibodies and recombinant proteins. KBI Biopharma is renowned for its innovative approach to bioprocess development and its commitment to quality, offering a comprehensive suite of services from early-stage development to commercial manufacturing. The company’s state-of-the-art facilities and experienced team enable it to deliver tailored solutions that meet the unique needs of its clients. With a strong market position and a track record of successful partnerships, KBI Biopharma continues to drive advancements in biopharmaceutical manufacturing, contributing to the growth of the industry.
DitchCarbon Score
How does KBI Biopharma Inc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
KBI Biopharma Inc's score of 57 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
KBI Biopharma Inc, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of JSR Corporation, which may influence its climate commitments and emissions reporting. As part of its corporate family, KBI Biopharma inherits climate initiatives and targets from JSR Corporation. However, there are no documented reduction targets or specific climate pledges listed for KBI Biopharma at this time. The absence of emissions data and reduction initiatives suggests that KBI Biopharma may still be in the process of establishing its own climate strategy or reporting framework. In summary, while KBI Biopharma Inc is linked to JSR Corporation's sustainability efforts, it currently lacks specific emissions data and defined climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 397,763,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | - |
| Scope 2 | 259,969,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - |
| Scope 3 | 629,484,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is KBI Biopharma Inc's Industry?
How Carbon Intensive is KBI Biopharma Inc's Location?
KBI Biopharma Inc's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
KBI Biopharma Inc has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
Vetter Pharma
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.